Company intelligence / Profile preview

LB Pharmaceuticals

New York, New York, United Stateslbpharma.us ↗

Ownership: Public · LBRX
Development stage: Phase 2

Overview

LB-102 showed positive Phase 2 results in schizophrenia with statistically significant improvements in PANSS scores across all tested doses. The drug was generally safe and well-tolerated with common adverse events including insomnia, headache, anxiety, and agitation. The company plans to initiate Phase 3 trials in Q4 2025.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

LP-102

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.4B
Total revenue: $0
Enterprise value: $1.1B

Beyond the preview

Go deeper on LB Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB Pharmaceuticals.

Explore the full profile